Results 101 to 110 of about 9,592 (241)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

Efectividad y seguridad de daclatasvir/ sofosbuvir con o sin ribavirina en pacientes infectados por el genotipo 3 del virus de la hepatitis C: resultados en práctica clínica real [PDF]

, 2019
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients.
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Mena, Álvaro, Pernas, Berta, Pértega-Díaz, Sonia, Rodríguez-Osorio, Iria   +8 more
core   +1 more source

Daclatasvir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation [PDF]

, 2012
A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally ...
Alcaide, Bacon, Berenguer, Berenguer, Bifano, Carrión, Chayama, Forman, Fridell, Gane, Gane, Garg, Guillouche, Hanouneh, Hézode, Jacobson, Kugelmas, Lai, Lee, Levitsky, Levitsky, Lok, Machicao, Naoum, Narang, Nettles, Pelletier, Picciotto, Poordad, Prieto, Schluger, Selzner, Sharma, Sharma, Sheiner, Sulkowski, Suzuki, Suzuki, Veldt, Verna, Weston, Zeuzem   +41 more
core   +1 more source

Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation [PDF]

, 2020
Osama Aboelfotoh Aly, Wael Ahmed Yousry, Nahla Mohamed Teama, Eman Mohammed Shona, Ahmed Mohamed ElGhandour   +4 more
openalex   +1 more source

Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon [PDF]

, 2017
Hepatitis C virus (HCV) genotype (GT) 3 is the second most prevalent of the seven HCV genotypes and exhibits the greatest resistance to the highly potent, direct-acting antivirals (DAAs) that are currently in use. Previously a stable cell line harbouring
Badhan, A, Harris, M, Kelly, L, Mbisa, JL, Roberts, GC   +4 more
core   +1 more source

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

Viruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche, Audrey Coilly, Anne-Marie Roque-Afonso, Didier Samuel   +3 more
doaj   +1 more source

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection [PDF]

, 2022
Simiso Sokhela, Bronwyn Bosch, Andrew Hill, Bryony Simmons, Joana Woods, Hilary Johnstone, Godspower Akpomiemie, Leah Ellis, Andrew Owen, Carmen Pérez Casas, François Venter   +10 more
openalex   +1 more source

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj